Alembic Pharma shares jump as it gets USFDA tentative approval for Bosutinib 400 mgAlembic Pharma shares jump as it gets USFDA tentative approval for Bosutinib 400 mg

Introduction

Leading Indian drug manufacturer received USFDA tentative approval for Bosutinib Tablets 400 mg, a kinase inhibitor for treatment of adult Ph positive chronic myelogenous leukemia.

Also Read: Brahmaputra Infrastructure wins big with ₹113 crore PWD Jammu order

Share price movement of Alembic Pharma

On January 12, 2026, Alembic Pharmaceuticals Ltd opened at ₹801.70, up 0.23% from its previous close of ₹799.90. The stock reached a high of ₹802.40 (0.31%) and a low of ₹786.35. By 2:49 PM, it traded at ₹799.70, down 0.03%, with a market cap of ₹15,719.15 crore.

Alembic Pharma Gets USFDA Nod

Alembic Pharmaceuticals Limited received USFDA tentative approval for its supplemental ANDA Bosutinib Tablets 400 mg, therapeutically equivalent to Bosulif 400 mg, for treatment of adult Ph positive chronic myelogenous leukemia.

Bosutinib is a kinase inhibitor indicated for adults with chronic phase Ph positive CML, newly diagnosed or resistant, and for accelerated or blast phase disease with resistance or intolerance therapy.

Alembic earlier received final approvals for 100 mg and 500 mg strengths; Bosutinib 400 mg market size is US$ 251 million, twelve months ending September 2025, IQVIA data according estimates.

Stock performance of Alembic Pharma for Period of 1 week, 6 months, and 1 year

Alembic Pharmaceuticals Ltd delivered a -4.48% return over the past week, declined 22.0% in the past 6 months, and fell 20.8% over the past year.

Also Read: E2E Networks boosts AI infra with NVIDIA B200 deployment in Chennai

Shareholding pattern of Alembic Pharma

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	69.70%	69.70%	69.70%
FII	4.20%	4.00%	4.00%
DII	16.20%	16.30%	16.50%
Public	9.80%	9.90%	9.90%

About Alembic Pharma

Alembic Pharmaceuticals Limited (NSE: APLLTD), founded in 1907, is a vertically integrated pharmaceutical company manufacturing and marketing generic medicines globally with USFDA approved facilities.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs

URL
Meta Title
Title Score
Meta Description